RxDoctor Payments Data

Lalbahadur Nagabhairu, MD

Gastroenterology · Mount Dora, FLNPI 1013956473

Payments from drug & device makers

$460in general payments, 2019–2025

Across 18 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Anx Robotica Corp$145
  • Evoke Pharma, Inc.$86
  • AbbVie$81
  • Medtronic$56
  • Boston Scientific$35
  • Regeneron Healthcare Solutions, Inc.$22
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$43895%
  • Education$225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Anx Robotica Corp2$145
Evoke Pharma, Inc.5$86
AbbVie5$81
Medtronic2$56
Boston Scientific1$35
Regeneron Healthcare Solutions, Inc.1$22
Intercept Pharmaceuticals, Inc.1$19
Neuraxis, Inc.1$16

How this compares

$460 in reported general payments places this provider in the 15th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$701,418
Medicare patients
1,817
Services billed
7,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase57$132,682
XifaxanRifaximin12$38,752
LinzessLinaclotide48$29,080
Mesalamine55$16,683
Ursodiol72$15,486
Omeprazole720$7,422
Colesevelam Hcl50$6,335
Sucralfate166$3,473
CholestyramineCholestyramine (With Sugar)32$2,839
Pantoprazole Sodium240$2,522
Nadolol48$1,625
Azithromycin38$995
Ondansetron OdtOndansetron26$834
Dicyclomine Hcl26$723
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl47$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$81$161,762105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Mount Dora

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →